Pfizer Ownership
| PFE Stock | USD 25.65 0.52 2.07% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 5.7 B | Current Value 5.7 B | Avarage Shares Outstanding 6.4 B | Quarterly Volatility 814.2 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Pfizer |
Pfizer Stock Ownership Analysis
About 68.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.58. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pfizer Inc has Price/Earnings To Growth (PEG) ratio of 0.18. The entity last dividend was issued on the 8th of November 2024. The firm had 1054:1000 split on the 17th of November 2020. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 79000 people. To find out more about Pfizer Inc contact DVM DVM at 212 733 2323 or learn more at https://www.pfizer.com.Besides selling stocks to institutional investors, Pfizer also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Pfizer's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Pfizer's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Pfizer Quarterly Liabilities And Stockholders Equity |
|
Pfizer Insider Trades History
Less than 1% of Pfizer Inc are currently held by insiders. Unlike Pfizer's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Pfizer's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Pfizer's insider trades
Pfizer Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pfizer is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pfizer Inc backward and forwards among themselves. Pfizer's institutional investor refers to the entity that pools money to purchase Pfizer's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Capital World Investors | 2024-09-30 | 53.7 M | Bank Of America Corp | 2024-06-30 | 52.4 M | Amundi | 2024-06-30 | 50.2 M | Legal & General Group Plc | 2024-06-30 | 46.6 M | Bank Of New York Mellon Corp | 2024-06-30 | 41.9 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 38.1 M | Jpmorgan Chase & Co | 2024-06-30 | 37.2 M | Goldman Sachs Group Inc | 2024-06-30 | 34.9 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 33.4 M | Vanguard Group Inc | 2024-09-30 | 516.2 M | Blackrock Inc | 2024-06-30 | 424.4 M |
Pfizer Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pfizer insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pfizer's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pfizer insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
John Young over a year ago Acquisition by John Young of tradable shares of Pfizer subject to Rule 16b-3 |
Pfizer's latest congressional trading
Congressional trading in companies like Pfizer Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Pfizer by those in governmental positions are based on the same information available to the general public.
| 2024-11-22 | Representative Laurel Lee | Acquired $15K to $50K | Verify | ||
| 2024-11-15 | Representative Greg Landsman | Acquired Under $15K | Verify | ||
| 2024-09-04 | Representative Kathy Manning | Acquired Under $15K | Verify | ||
| 2024-08-21 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
| 2024-08-20 | Representative C Scott Franklin | Acquired $15K to $50K | Verify | ||
| 2024-06-14 | Senator Tommy Tuberville | Acquired $15K to $50K | Verify | ||
| 2024-06-13 | Senator Tommy Tuberville | Acquired $15K to $50K | Verify | ||
| 2024-06-12 | Representative Roger Williams | Acquired Under $15K | Verify | ||
| 2024-03-15 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2024-03-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2024-03-02 | Representative Earl Blumenauer | Acquired Under $15K | Verify | ||
| 2024-01-18 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2024-01-17 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2024-01-16 | Senator Jerry Moran | Acquired Under $15K | Verify | ||
| 2024-01-12 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
| 2024-01-11 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
| 2024-01-08 | Senator John Boozman | Acquired Under $15K | Verify | ||
| 2024-01-07 | Senator John Boozman | Acquired Under $15K | Verify | ||
| 2023-08-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-07-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-04-17 | Representative Carol Devine Miller | Acquired Under $15K | Verify | ||
| 2023-02-24 | Representative Michael Patrick Guest | Acquired Under $15K | Verify | ||
| 2022-04-06 | Representative Lois Frankel | Acquired Under $15K | Verify | ||
| 2022-02-27 | Representative Lois Frankel | Acquired Under $15K | Verify | ||
| 2021-11-03 | Representative Zoe Lofgren | Acquired Under $15K | Verify | ||
| 2021-06-09 | Representative Earl Blumenauer | Acquired Under $15K | Verify | ||
| 2020-11-22 | Representative Bob Gibbs | Acquired Under $15K | Verify | ||
| 2020-11-11 | Representative Ed Perlmutter | Acquired Under $15K | Verify | ||
| 2020-09-04 | Representative K Michael Conaway | Acquired $15K to $50K | Verify | ||
| 2020-08-13 | Representative Ed Perlmutter | Acquired Under $15K | Verify | ||
| 2020-08-04 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
| 2020-08-03 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
| 2020-07-11 | Representative Mo Brooks | Acquired Under $15K | Verify | ||
| 2020-07-01 | Representative John A Yarmuth | Acquired Under $15K | Verify | ||
| 2020-02-24 | Representative Lois Frankel | Acquired Under $15K | Verify | ||
| 2019-02-07 | Representative Robert J Wittman | Acquired Under $15K | Verify | ||
| 2018-12-06 | Senator David Perdue | Acquired Under $15K | Verify | ||
| 2017-08-06 | Senator David Perdue | Acquired Under $15K | Verify | ||
| 2017-06-06 | Senator David Perdue | Acquired Under $15K | Verify | ||
| 2017-03-15 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2017-03-14 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2016-12-07 | Senator John Hoeven | Acquired $50K to $100K | Verify | ||
| 2016-03-01 | Senator David Perdue | Acquired Under $15K | Verify |
Pfizer Outstanding Bonds
Pfizer issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pfizer Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pfizer bonds can be classified according to their maturity, which is the date when Pfizer Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PFIZER INC 4125 Corp BondUS717081ED10 | View | |
| PFIZER INC 4 Corp BondUS717081EC37 | View | |
| PFIZER INC 3 Corp BondUS717081EA70 | View | |
| PFIZER INC 44 Corp BondUS717081DK61 | View | |
| PFIZER INC 275 Corp BondUS717081DV27 | View | |
| US717081DT70 Corp BondUS717081DT70 | View | |
| PFIZER INC Corp BondUS717081EZ22 | View | |
| PFE 175 18 AUG 31 Corp BondUS717081FB45 | View |
Pfizer Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 4th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 3rd of October 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.98) | Dividend Share 1.67 | Earnings Share 0.75 | Revenue Per Share 10.493 | Quarterly Revenue Growth 0.312 |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.